Prospective study of evaluating the efficacy and safety of Radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases

Trial Profile

Prospective study of evaluating the efficacy and safety of Radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Sep 2017

At a glance

  • Drugs Radium 223 chloride (Primary)
  • Indications Bone metastases; Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 21 Sep 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top